Medical Journal of The Islamic Republic of Iran (MJIRI)
Iran University of Medical Sciences
Sat, Nov 1, 2025
[Archive]
Volume 39, Issue 1 (1-2025)
Med J Islam Repub Iran 2025 |
Back to browse issues page
Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
Taher M, Esfandiari M, Abredari H, Aghazade Sarhangipour K, Taheri L, Ghanbari-Afra L et al . Efficacy of Sequential Metronidazole and Furazolidone with Proton Pump Inhibitors versus Standard Regimen in Treating Helicobacter pylori Infection: A Randomized Controlled Trial. Med J Islam Repub Iran 2025; 39 (1) :1144-1149
URL: http://mjiri.iums.ac.ir/article-1-9233-en.html
URL: http://mjiri.iums.ac.ir/article-1-9233-en.html
Mohammad Taher 
, Mahdieh Esfandiari , Hamid Abredari , Kouros Aghazade Sarhangipour , Leila Taheri , Leila Ghanbari-Afra , Mohammad Reza Rouhani
, Mahdieh Esfandiari , Hamid Abredari , Kouros Aghazade Sarhangipour , Leila Taheri , Leila Ghanbari-Afra , Mohammad Reza Rouhani
Department of Internal Medicine, Saveh University of Medical Sciences, Saveh, Iran , mohamadreza.rohani@yahoo.com
Abstract: (128 Views)
Background: Helicobacter pylori infection is a prevalent global health issue, especially in developing countries. Due to increasing antibiotic resistance, sequential therapy regimens have been proposed as alternatives to standard treatment. This study aimed to evaluate the efficacy and safety of a 1-week sequential regimen containing furazolidone and metronidazole compared to the standard triple therapy for H. pylori eradication.
Methods: In this randomized, parallel-group clinical trial, 110 patients with confirmed H. pylori infection were randomly assigned to either the intervention group (sequential therapy) or the control group (standard regimen). The primary outcome was H. pylori eradication assessed by stool antigen test 4 weeks after treatment. Secondary outcomes included adverse effects. Data were analyzed using chi-square and other appropriate statistical tests.
Results: The eradication rate was significantly higher in the intervention group than in the control group (76.4% vs. 56.4%, χ² = 4.928, P = 0.043). Adverse events were less frequent in the intervention group, including nausea (16.4% vs. 23.6%, P = 0.03), altered taste (10.9% vs. 18.2%, P = 0.002), loss of appetite (7.3% vs. 14.5%, P = 0.006), and dizziness (5.5% vs. 0%, P = 0.048).
Conclusion: The 1-week sequential regimen demonstrated significantly higher eradication rates and better tolerability compared to the standard triple therapy. This approach may offer a more effective and safer option for treating H. pylori infection.
Methods: In this randomized, parallel-group clinical trial, 110 patients with confirmed H. pylori infection were randomly assigned to either the intervention group (sequential therapy) or the control group (standard regimen). The primary outcome was H. pylori eradication assessed by stool antigen test 4 weeks after treatment. Secondary outcomes included adverse effects. Data were analyzed using chi-square and other appropriate statistical tests.
Results: The eradication rate was significantly higher in the intervention group than in the control group (76.4% vs. 56.4%, χ² = 4.928, P = 0.043). Adverse events were less frequent in the intervention group, including nausea (16.4% vs. 23.6%, P = 0.03), altered taste (10.9% vs. 18.2%, P = 0.002), loss of appetite (7.3% vs. 14.5%, P = 0.006), and dizziness (5.5% vs. 0%, P = 0.048).
Conclusion: The 1-week sequential regimen demonstrated significantly higher eradication rates and better tolerability compared to the standard triple therapy. This approach may offer a more effective and safer option for treating H. pylori infection.
Keywords: Helicobacter Pylori, Furazolidone, Proton Pump Inhibitor (PPI), Metronidazole, Antibiotics
Type of Study: Original Research |
Subject:
Gastroenterology
Send email to the article author
| Rights and permissions | |
 |
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. |
